We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
-7.49%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.45B
AUM Growth
-$331M
Cap. Flow
-$447M
Cap. Flow %
-18.22%
Top 10 Hldgs %
43.96%
Holding
111
New
16
Increased
20
Reduced
24
Closed
16

Top Buys

Rank Stock Value
1
MIRM icon
Mirum Pharmaceuticals
MIRM
+$42.3M
2
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$42.2M
3
AERI
Aerie Pharmaceuticals
AERI
+$35.2M
4
SWTX
SpringWorks Therapeutics
SWTX
+$24.8M
5
CNC icon
Centene
CNC
+$20.3M

Top Sells

Rank Stock Value
1
NTRA icon
Natera
NTRA
+$27.7M
2
IMMU
Immunomedics Inc
IMMU
+$26M
3
STAA icon
STAAR Surgical
STAA
+$25.8M
4
NVRO
NEVRO CORP.
NVRO
+$25M
5
NVTA
Invitae Corporation
NVTA
+$23.4M

Sector Composition

Rank Sector Weight
1 Healthcare 71.17%
2 Financials 0.3%
3 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TNDM icon
26
Tandem Diabetes Care
TNDM
$1.24B
$26.8M 1.09%
454,334
+301,834
+198% +$19.3M
EDIT icon
27
Editas Medicine
EDIT
$442M
$26.4M 1.07%
1,158,841
– –
DFBHU
28
DELISTED
DFB Healthcare Acquisitions Corp. Unit
DFBHU
$25.8M 1.05%
2,500,000
– –
AXGN icon
29
Axogen
AXGN
$2.1B
$23M 0.94%
1,842,330
+951,024
+107% +$15.7M
SWTX
30
DELISTED
SpringWorks Therapeutics
SWTX
$22.8M 0.93%
+1,050,888
New +$24.8M
XERS icon
31
Xeris Biopharma Holdings
XERS
$1.48B
$22.7M 0.93%
2,308,666
-71,235
-3% -$800K
MOH icon
32
Molina Healthcare
MOH
$12B
$21.6M 0.88%
197,056
+47,056
+31% +$6.1M
RCKT icon
33
Rocket Pharmaceuticals
RCKT
$375M
$20.7M 0.84%
1,773,938
+636,796
+56% +$7.9M
DCPH
34
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$20.2M 0.82%
594,725
-12,908
-2% -$382K
ADUS icon
35
Addus HomeCare
ADUS
$2.08B
$20.1M 0.82%
252,915
– –
ARVN icon
36
Arvinas
ARVN
$517M
$19.9M 0.81%
921,234
– –
MRTX
37
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$18.2M 0.74%
233,000
-31,600
-12% -$2.97M
HUM icon
38
Humana
HUM
$47.8B
$17.1M 0.7%
67,000
– –
WVE icon
39
Wave Life Sciences
WVE
$1.1B
$16.6M 0.68%
807,727
+138,467
+21% +$3.17M
ARDX icon
40
Ardelyx
ARDX
$1.26B
$16M 0.65%
3,400,410
-60,888
-2% -$211K
PTCT icon
41
PTC Therapeutics
PTCT
$6.47B
$15.9M 0.65%
471,000
– –
RETA
42
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$15.8M 0.64%
197,000
– –
LKFT
43
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.9B
$15.4M 0.63%
101,010
– –
ANAB icon
44
AnaptysBio
ANAB
$1.49B
$14.9M 0.61%
425,443
-115,086
-21% -$5.48M
DPLO
45
DELISTED
DIPLOMAT PHARMACY, INC.
DPLO
$14.7M 0.6%
2,996,328
-4,040,342
-57% -$22.6M
TPTX
46
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$14.6M 0.59%
387,545
+100,000
+35% +$4.35M
BOLD
47
DELISTED
Audentes Therapeutics, Inc
BOLD
$13.9M 0.57%
493,901
– –
SYRS
48
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$13.2M 0.54%
126,895
– –
GBT
49
DELISTED
Global Blood Therapeutics, Inc.
GBT
$13M 0.53%
268,100
+33,100
+14% +$1.72M
AVDL
50
DELISTED
Avadel Pharmaceuticals
AVDL
$11.3M 0.46%
2,722,241
– –
1
2
3 4 5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q3 2019 Portfolio in Review

As of Q3 2019, Deerfield Management held 111 positions worth $2.45B, down 12% from $2.78B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Deerfield Management withdrew a net $447M in Q3 2019, closing 16 positions and reducing 24 holdings. Its most notable exit was Natera, an estimated $27.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 71% of assets, up from 68% a quarter earlier, followed by Financials and Consumer Discretionary.

Against the trend, Deerfield Management opened a new position in Mirum Pharmaceuticals worth $34.7M.

  • Deerfield Management's largest Q3 2019 buy was Mirum Pharmaceuticals: 3,448,912 shares worth $34.7M.
  • Deerfield Management added most to Rhythm Pharmaceuticals in Q3 2019, an estimated $42.2M increase.
  • Deerfield Management's biggest Q3 2019 reduction was Immunomedics Inc, cutting an estimated $26M.
  • Deerfield Management fully exited Natera in Q3 2019, selling an estimated $27.7M.
  • Deerfield Management's ten largest holdings make up 44% of its $2.45B portfolio in Q3 2019.
  • Deerfield Management opened 16 new positions and closed 16 in Q3 2019.
  • Deerfield Management's portfolio value fell 12% quarter-over-quarter to $2.45B.

Based on Deerfield Management's 13F filing for Q3 2019, filed 14 Nov 2019.